We show synergistic interaction between CARM1 targeting through small molecule inhibition or genetic ablation plus either lenalidomide or pomalidomide against both IMiD-sensitive and IMiD-insensitive MM cells. The gene discussed is CARM1; the disease is Miyoshi myopathy.